Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib

Who is this study for? Patients with rheumatoid arthritis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: Baricitinib treatment for 12 months Biologics treatment for 12 months Tofacitinib treatment for 12 months

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: No
View:

• RA patients

Locations
Other Locations
Japan
Yukio Nakamura
Recruiting
Matsumoto
Time Frame
Start Date: November 21, 2018
Estimated Completion Date: November 20, 2025
Participants
Target number of participants: 90
Treatments
Active Comparator: BARI
Active Comparator: Bio
Active Comparator: Tofa
Related Therapeutic Areas
Sponsors
Leads: Shinshu University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials